Compare · ECOR vs TMDX
ECOR vs TMDX
Side-by-side comparison of electroCore Inc. (ECOR) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ECOR and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.65B, about 35.2x ECOR ($75.3M).
- Over the past year, ECOR is up 62.7% and TMDX is down 39.8% - ECOR leads by 102.5 points.
- TMDX has been more active in the news (2 items in the past 4 weeks vs 1 for ECOR).
- TMDX has more recent analyst coverage (20 ratings vs 2 for ECOR).
- Company
- electroCore Inc.
- TransMedics Group Inc.
- Price
- $7.99-4.99%
- $70.82-7.52%
- Market cap
- $75.3M
- $2.65B
- 1M return
- -29.51%
- -18.36%
- 1Y return
- +62.73%
- -39.77%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2019
- News (4w)
- 1
- 2
- Recent ratings
- 2
- 20
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest ECOR
- Director Errico Thomas J. bought $49,082 worth of shares (5,000 units at $9.82), increasing direct ownership by 1% to 363,904 units (SEC Form 4)
- Amendment: Officer Fox Michael bought $49,004 worth of shares (5,000 units at $9.80), increasing direct ownership by 4% to 130,000 units (SEC Form 4)
- Officer Fox Michael was granted 5,000 shares, increasing direct ownership by 4% to 130,000 units (SEC Form 4)
- Director Theofilos James Charles was granted 11,123 shares, increasing direct ownership by 47% to 34,670 units (SEC Form 4)
- Director Goldstein Julie Ann was granted 11,123 shares, increasing direct ownership by 11% to 112,510 units (SEC Form 4)
- Director Wilber Patricia was granted 11,123 shares, increasing direct ownership by 15% to 83,448 units (SEC Form 4)
- Director Errico Thomas J. was granted 15,572 shares, increasing direct ownership by 5% to 358,904 units (SEC Form 4)
- Director Bonfiglioli Elena was granted 11,123 shares, increasing direct ownership by 36% to 41,672 units (SEC Form 4)
- Officer Fox Michael was granted 55,000 shares, increasing direct ownership by 79% to 125,000 units (SEC Form 4)
- Officer Lev Joshua S. was granted 55,000 shares, increasing direct ownership by 65% to 139,889 units (SEC Form 4)
Latest TMDX
- Barclays initiated coverage on TransMedics Group with a new price target
- SEC Form 3 filed by new insider Araujo Fernando N.
- Director Weill David bought $109,058 worth of shares (1,336 units at $81.63), increasing direct ownership by 9% to 16,392 units (SEC Form 4)
- TransMedics Group Inc. filed SEC Form 8-K: Regulation FD Disclosure
- TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
- TransMedics to Present at Upcoming September Investor Conferences
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results